Table 4 Adverse events by preferred term, regardless of relationship to everolimus
n(%) | Everolimus (N = 18) | |||
|---|---|---|---|---|
All grades | Grade 3 | Grade 4 | Grade 5 | |
Mucositis oral | 18(100%) | 2(11.1%) | – | – |
Irregular menstruation | 11(91.7%) | 3(25.0%) | – | – |
Abdominal pain | 14(77.8%) | 1(5.6%) | – | – |
Hypertriglyceridemia | 13(72.2%) | – | – | – |
Headache | 12(66.7%) | – | – | – |
Diarrhea | 11(61.1%) | – | – | – |
Upper respiratory infection | 10(55.6%) | – | – | – |
Proteinuria | 9(50%) | 1(5.6%) | – | – |
Malaise | 9(50%) | – | – | – |
Rash acneiform | 8(44.4%) | – | – | – |
Cholesterol high | 8(44.4%) | – | – | – |
Fever | 6(33.3%) | – | – | – |
Urinary tract infection | 5(27.8%) | – | – | – |
Hematuria | 5(27.8%) | – | – | – |
Alkaline phosphatase increased | 5(27.8%) | – | – | – |
Constipation | 4(22.2%) | – | – | – |
GGT increased | 4(22.2%) | – | – | – |
Hypophosphatemia | 4(22.2%) | – | – | – |
Seizures | 3(16.7%) | – | – | – |
Pneumonitis | 2(11.1%) | 1(5.6%) | – | 1(5.6%) |
Vomiting | 2(11.1%) | 1(5.6%) | – | – |
Lymphocyte count decreased | 2(11.1%) | – | – | – |
Anemia | 2(11.1%) | – | – | – |
Renal hemorrhage | 1(5.6%) | – | – | 1(5.6%) |
Neutrophil count decreased | 1(5.6%) | – | – | – |
Hyperuricemia | 1(5.6%) | – | – | – |
Creatinine increased | 1(5.6%) | – | – | – |